Clonal evolution from B-cell acute lymphoblastic leukemia with BCR::ABL1 multilineage involvement to acute myeloid leukemia after multiple anti-CD19 chimeric antigen receptor T-cell therapy

by Mei-Jing Liu, Lan Dai, Li Yao, Kai-Wen Tan, Han-Yu Cao, Si-Man Huang, Chao-Ling Wan, Yuan-Hong Huang, Yang Zhang, Wen-Jie Gong, and Sheng-Li Xue

Received: Apr 2, 2024.
Accepted: June 25, 2024.

Citation: Mei-Jing Liu, Lan Dai, Li Yao, Kai-Wen Tan, Han-Yu Cao, Si-Man Huang, Chao-Ling Wan, Yuan-Hong Huang, Yang Zhang, Wen-Jie Gong, and Sheng-Li Xue. Clonal evolution from B-cell acute lymphoblastic leukemia with BCR::ABL1 multilineage involvement to acute myeloid leukemia after multiple anti-CD19 chimeric antigen receptor T-cell therapy. Haematologica. 2024 July 4. doi: 10.3324/haematol.2024.285574 [Epub ahead of print]

Publisher’s Disclaimer.
E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors’ final approval; the final version of the manuscript will then appear in a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process.
Clonal evolution from B-cell acute lymphoblastic leukemia with 
*BCR::ABL1* multilineage involvement to acute myeloid leukemia after multiple anti-CD19 chimeric antigen receptor T-cell therapy

Mei-Jing Liu¹,²,* , Lan Dai¹,²,* , Li Yao¹,²,* , Kai-Wen Tan¹,², Han-Yu Cao¹,², Si-Man Huang¹,², Chao-Ling Wan¹,², Yuan-Hong Huang¹,², Yang Zhang³, Wen-Jie Gong¹,²,#, Sheng-Li Xue¹,²,#

¹National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;  
²Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China;  
³Department of Hematology Canglang Hospital of Suzhou, Suzhou, China;

**Running Title:** Clonal evolution from ALL to AML after CAR T-cell

*Mei-Jing Liu, Lan Dai and Li Yao contributed equally as first authors.

**Corresponding Author:**  
Sheng-Li Xue and Wen-Jie Gong, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Shizi Street 188, Suzhou 215006, China. E-mail: slxue@suda.edu.cn and gongwenjie45@126.com

**Data sharing statement:** Please email the corresponding authors.  
**Trial Registration:** ClinicalTrials.gov identifier: NCT03984968

**Key words:** Clonal evolution, B-ALL, Anti-CD19 CAR T-cell, Lineage switch, *BCR::ABL1* multilineage involvement

**Acknowledgments:** This study acknowledged the data from the First Affiliated Hospital of Soochow University and technical support from shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.
**Funding:** This work was supported by the grants from the National Key R&D Program of China (2022YFC2502700), National Natural Science Foundation of China (Grant No. 81970138, 82270165), Jiangsu Province Natural Science Foundation of China (Grant No. BK20221235), Jiangsu Province “333” Project, Social Development Project of the Science and Technology Department of Jiangsu (Grant No. BE2021649), Boxi Clinical Research Project (Grant No. BXLC008) and Gusu Key Medical Talent Program (Grant No. GSWS2019007), Translational Research Grant of NCRCH (Grant No. 2021ZKQ04).

**Disclosures:** No conflicts of interest to disclose.

**Author contributions:** S.L.X and W.J.G designed the study and edited manuscript. M.J.L, L.D and L.Y collected, analyzed the data, and wrote the manuscript. K.W.T, S.M.H, C.L.W, Y.H.H, Y.Z and H.Y.C collected the data. W.J.G and S.L.X read the manuscript and gave comments. All authors reviewed the manuscript.
Clonal evolution in leukemia generally arises under the selection pressure of cytotoxic chemotherapy and targeted therapies. Unlike B-cell acute lymphoblastic leukemia (B-ALL) relapse associated with the acquisition of drug resistance mutations in chemotherapy, clonal evolution after CD19-targeted immunotherapies including blinatumomab and anti-CD19 chimeric antigen receptor (anti-CD19 CAR) T-cell therapy, is mainly determined by the immunophenotype of blasts. Downregulation of CD19 and selection of the CD19-negative subclones are potential mechanisms of CD19-negative relapse. With the widespread use of cell surface antigen-targeted therapies, lineage switch is being observed with increasing frequency. Recently, a study reported that among patients with lineage switch after T-cell engaging therapies, 48.90% (23/47) patients received CAR T-cell and 51.10% (24/47) patients received blinatumomab prior to lineage switch. Here, we present a rare case of patient with B-ALL with BCR::ABL1 multilineage involvement who developed immunoglobulin heavy chain (IGH) clonal evolution accompanied by acute myeloid leukemia (AML) phenotypic and morphological changes after receiving multiple times of anti-CD19 CAR T-cell consolidation therapy.

A 56-year-old woman presented with fatigue and excessive sweating in December 2021. Peripheral blood counts revealed elevated white blood cell count (185.32×10⁹/L), anemia (hemoglobin, 96 g/L) and thrombocytopenia (14×10⁹/L). Bone marrow aspirate smears exhibited intermediate-sized blasts with scant, agranular cytoplasm, delicate chromatin, and inconspicuous nucleoli. Morphology analysis of bone marrow aspiration indicated that lymphoid blasts comprised 73.50% of the bone marrow mononuclear cells. Immunophenotyping confirmed the diagnosis of B-ALL expressing CD34, CD10, CD19, and cytoplasmic CD79a (cCD79a). Blasts expressed CD13, CD33 and were negative for other myeloid markers (HLA-DR, MPO, etc). Chromosome analysis revealed 46,XX,t(9;22)(q34;q11)[2]/45,idem,-7[5]/45,idem,-7,20q-[3], and quantitative PCR confirmed the BCR::ABL1 (b2a2/b3a2) fusion. Next-generation sequencing (NGS) of hotspot mutations showed mutations in RUNX1 with a variant allele frequency of 44.29%, MYD88 with a variant
allele frequency of 50.80%, and no ABL1 kinase domain mutation was detected (Table 1). Consequently, bone marrow aspiration analysis by morphology, immunophenotyping, cytogenetics, and molecular genetics suggested Philadelphia-positive (Ph+) B-ALL. After dexamethasone pretreatment and induction therapy with idarubicin (10 mg*1d) + vindesine (4 mg*1d) combined with imatinib, complete remission (CR) was achieved, confirmed by bone marrow aspiration examination in January 2022. However, flow cytometry (FCM) analysis revealed that the measurable residual disease (MRD) was 18.07% in cerebrospinal fluid (CSF) but negative in bone marrow, indicating isolated central nervous system leukemia (CNSL) in March 2022. The blasts in CSF became negative after two courses of triple intrathecal chemotherapy (methotrexate + cytarabine + dexamethasone) and chemotherapy of high-dose methotrexate (3 g/m²) with medium-dose cytarabine (2 g/m²).

Then the patient was recruited into the clinical trial (NCT03984968), incorporating first-time anti-CD19 CAR T-cell therapy, followed by three cycles’ consolidation therapy of anti-CD19 CAR T-cell combined with CD19+ feeding T cells (FTCs, autologous T cells transduced with a CD19 gene expression vector) and tyrosine kinase inhibitors (TKIs) to eliminate MRD. The supplementation with CD19+ FTCs can restore the anti-CD19 CAR T-cells’ lost response to residual CD19+ blasts. This research has been approved by the Ethics Committee of the First Affiliated Hospital of Soochow University. At 28 days after the first dose of anti-CD19 CAR T-cell infusion, this patient had a hypocellular marrow with MRD of <1.4×10⁻⁴ measured by FCM on a bone marrow aspirate, along with 2263 BCR::ABL1 copies/10000 ABL1 copies (Table 1). Therefore, this patient discontinued imatinib and switched to dasatinib maintenance therapy. After three cycles’ consolidation therapy, this patient achieved MRD negative CR and 0.99% BCR::ABL1 fusion. However, she relapsed at three months after the last cycle of anti-CD19 CAR T-cell consolidation therapy. Her bone marrow aspirate smears showed the emergence of blasts with more abundant cytoplasm (Figure 1G). Bone marrow aspirate analysis by FCM showed 73.80% of blasts were positive for HLA-DR, CD13, CD33, and CD117, whereas CD19 and other B-lineage antigens were absent (Table 1).
and Figure 1H-L). Cytogenetic studies of the bone marrow showed the original t(9;22)(q34;q11) (Table 1). Except for the newly emerged AML blasts, there was no evidence of residual B-ALL blasts. NGS revealed persistence of the mutation in RUNX1 (27.70%) and MYD88 (48.90%), additional FAT1 (49.80%), IKZF1 (25.40%), and SETD2 (31.50%). The patient achieved sustained CR after re-induction of dasatinib and venetoclax. Subsequently, the patient intermittently used dasatinib as maintenance therapy and has remained in CR.

Lineage switch is a rare phenomenon characterized by the transformation of acute leukemia from one cell lineage to another, while maintaining the original cytogenetic or molecular aberrations and/or clonal immunoglobulin rearrangement patterns2,4,6. In this case, myeloid characteristics were absent at B-ALL diagnosis but became evident upon AML relapse. The patient retained the BCR::ABL1 fusion and IGH rearrangement upon AML relapse. Furthermore, we observed dynamic changes in IGH subclones. During treatment, the IGH gene may undergo new rearrangements based on the original, disappear entirely with new ones appearing, or alter non-major clone numbers and proportions7. In this case, the IGH rearrangement in bone marrow mononuclear cells by NGS revealed the primary clones 1 and 2 at initial diagnosis of B-ALL disappeared after anti-CD19 CAR T-cell treatment, while clones 3 and 4 remained and became the primary clones upon AML relapsed (Figure 2A). In addition, the shared mutational profile between the original B-ALL and the emergent AML (Table 1) supported that this patient suffered relapse with clonally related AML after anti-CD19 CAR T-cell therapy.

Recently, a new subset of B-ALL which appears more closely related to chronic myeloid leukemia (CML) presenting in lymphoid blast phase (LBP) was reported in International Consensus Classification (ICC) of Myeloid Neoplasms and Acute Leukemia8. The CML-like disease is characterized by the presence of BCR::ABL1 fusion in both granulocytes and blasts. BCR::ABL1 fusion following treatment shows high level positivity whereas both FCM and molecular MRD methods show no or little evidence of MRD contributes to distinguishing this new subset8. We reviewed the chromosome specimen at the initial diagnosis of B-ALL. The
BCR::ABL1 fusion was detected not only in B-ALL blasts but also in granulocytes by fluorescence in situ hybridization (FISH) detection (Figure 2B). Besides, quantitative PCR studies for BCR::ABL1 fusion following one month after the first time CAR T-cell therapy showed high level positivity when FCM showed little evidence of MRD (Figure 2C). Therefore, this patient should be diagnosed as B-ALL with BCR::ABL1 multilineage involvement.

The transition to a myeloid lineage in B-ALL following anti-CD19 CAR T-cell therapy is a rare event, particularly when accompanied by IGH clonal evolution. Previous studies have revealed the high frequency of IGH rearrangement clones in AML9,10. We utilized a sensitive NGS method to detect IGH rearrangements and founded that clone 3 and 4 could be detected at both initial B-ALL diagnosis and AML relapse. In addition, the BCR::ABL1 fusion, along with mutations of RUNX1 and MYD88, consistently accompanied AML relapse. Thus, it is highly probable that clones 3 and 4 represent relapsed AML blasts. We assumed that: (1) AML blasts may arise from the original B-ALL, especially from blasts that partially expressed CD13 and CD33 (Figure 2D). Baseline myeloid antigen co-expression was observed in the majority of patients potentially undergoing lineage switch4. These B-ALL blasts undergo transcription factor-mediated reprogramming after immunotherapy, leading to a lineage switch towards myeloid cells as a mechanism for immune escape2. (2) AML blasts exhibiting IGH rearrangement and BCR::ABL1 fusion may stem from the minor AML clones at the initial B-ALL diagnosis (Figure 2D). However, given the relatively low abundance of clones 3 and 4 identified at the time of B-ALL diagnosis, the precise phenotypic characteristics of these clones as defined by FCM remain uncertain. The concurrent presence of BCR::ABL1 fusion and IGH rearrangement in both B-ALL and AML blasts suggests that the aberrant myeloid cells likely originate from progenitor cells harboring BCR::ABL1 fusion, indicating an aberrant differentiation pathway (Figure 2D). Previous studies have suggested that early genetic mutations can cause progenitor cells to develop abnormally, with these abnormalities remaining stable or changing over time due to treatment and further genetic changes11,12.
Clonal evolution may contribute to therapy resistance, and treatment may also accelerate the evolutionary process. The observation that multiple prior cycles of chemotherapy and TKIs did not induce AML underscores the likely acquisition a myeloid phenotype subsequent to anti-CD19 CAR T-cell therapy. CD19-positive blasts responded well to anti-CD19 CAR T-cell treatment, while residual CD19-negative blasts displayed resistance. Additionally, CD19-negative relapse resulting from lineage switching tends to manifest approximately 1-2 months after anti-CD19 CAR T-cell therapy\textsuperscript{13-15}. In this case, AML relapse occurred 11 months after the initial anti-CD19 CAR T-cell infusion, during which the patient received multiple rounds of CAR T-cell therapy. Consequently, AML cell populations at relapse likely evolved from sub-clonal populations present at the B-ALL diagnosis under significant selective pressure.

In summary, this case may partially suggest the potential mechanism of B-ALL with $BCR::ABL1$ multilineage involvement and provide a novel mechanism of immune escape in B-ALL. The new subset of Ph+ B-ALL may have high-risk of transforming to AML under the pressure of CD19-targeted immunotherapy. In B-ALL with $BCR::ABL1$ multilineage involvement, no relevant prognostic feature applicable for therapy tailoring was found so far, multicenter and prospective studies are needed.
Reference


Table 1. The summary of abnormalities found at the time of B-ALL diagnosis and AML relapse.

<table>
<thead>
<tr>
<th></th>
<th>B-ALL at diagnosis</th>
<th>Pre 1st CAR-T cell infusion</th>
<th>Day28 post 1st CAR-T cell infusion</th>
<th>AML at relapse</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Immunophenotype</strong></td>
<td>CD34+, CD10+, CD19+, CD33+, CD117dim, CD45dim, CD7-, HLA-DR-, CD2-, CD15-, CD11B-, CD64-, CD56-, CD33-, CD3-, CD4-, CD8-, CD64-, CD56-, CD34+, CD123+, CD33+, CD22+, CD20-, CD10+, CD19+, CD38+, CD34+</td>
<td>CD81+, CD123+, CD33+, CD22+, CD20-, CD10+, CD19+, CD38+, CD34+, CD45+</td>
<td>CD7-, CD134+, HLA-DR+, CD10-, CD20-, CD19-, CD14-, CD13+, CD33+, CD2-, CD17+, CD15-, CD11B-, CD64-, CD56-, CD34+, CD4-, CD8-, CD3-, CD45s</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CD81+, CD123+, CD33+, CD22+, CD20-, CD10+, CD19+, CD38+, CD34+, CD45+</td>
<td>CD7-, CD134+, HLA-DR+, CD10-, CD20-, CD19-, CD14-, CD13+, CD33+, CD2-, CD17+, CD15-, CD11B-, CD64-, CD56-, CD34+, CD4-, CD8-, CD3-, CD45s</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cytogenetics</strong></td>
<td>46,XX,t(9;22)(q34;q11) [2]/45,idem,-7 [5]/45.idem,-7.20q-[3]</td>
<td>Not done</td>
<td>Not done</td>
<td>46,XX,t(9;22)(q34;q11) [5]/46.XX[5]</td>
</tr>
<tr>
<td><strong>MRD by FCM</strong></td>
<td>84.66%</td>
<td>(-)</td>
<td>&lt;1.4 x 10E-4</td>
<td>73.80%</td>
</tr>
<tr>
<td><strong>BCR::ABL1 by q-PCR</strong></td>
<td>(+)</td>
<td>(-)</td>
<td>22.63%</td>
<td>103.47%</td>
</tr>
<tr>
<td><strong>Mutations</strong></td>
<td>RUNX1, MYD88 mutations positive</td>
<td>(-)</td>
<td>(-)</td>
<td>RUNX1, FAT1, IKZF1, MYD88, SETD2 mutations positive</td>
</tr>
</tbody>
</table>

**Abbreviations:** MRD, measurable residual disease; FCM, flow cytometry.
Figure Legends

Figure 1. Distinct morphologic and immunophenotypic features of initial B-ALL blasts and AML blasts following lineage switch. (A) The lymphoblasts of B-ALL had scant cytoplasm, round nuclei, fine chromatin, and inconspicuous nucleoli. (B-F) The lymphoblasts (A cell group, SSdim and CD45dim) expressed CD19, CD10, cCD79a, CD34, CD13 and CD33. They were negative for HLA-DR and MPO. (G) The myeloid blasts of AML had abundant cytoplasm, folded nuclei, fine chromatin, and occasional prominent nucleoli. (H-L) The myeloid blasts (A cell group, SSdim and CD45dim) expressed HLA-DR, CD13, CD33, and CD117, yet they were negative for CD19, CD10 and cCD79a.

Figure 2. We confirmed the patient belonged to the subset of Ph+ B-ALL with BCR::ABL1 multilineage involvement, and assumed the models of AML relapse from B-ALL after anti-CD19 CAR T-cell therapy. (A) The primary clones 1 and 2 at initial diagnosis of B-ALL disappeared after anti-CD19 CAR T-cell treatment, while clones 3 and 4 expanded and became the primary clones upon AML relapse. (B) FISH detection revealed BCR::ABL1 fusion not only in B-ALL blasts (white arrow) but also in granulocytes (red arrow). (C) The presence of BCR::ABL1 fusion detected by PCR (solid line) was inconsistent with the MRD as measured by FCM (dashed line). (D) Models of AML relapse with BCR::ABL1 fusion and IGH rearrangement from B-ALL with BCR::ABL1 multilineage involvement. (1) B-ALL blasts expressing partial CD13 and CD33 experienced downregulation of CD19 expression, and upregulation of CD13 and CD33, ultimately resulting in AML relapse. (2) The minor AML blasts, undetected at the initial B-ALL diagnosis, expanded after multiple anti-CD19 CAR T-cell treatments that eliminated B-ALL, ultimately leading to AML relapse.
Figure 2

A) The proportion of IGH rearrangement clones

B) Image of cells

C) Graph showing MRD levels before CAR-T, 1 month after CAR-T, AML at relapse, and remission

D) Diagram showing the process from progenitor cell to Precursor cell, then to B-ALL at diagnosis, CAR T-cell Therapy, and AML at relapse.